Immunosuppressant everolimus reduced the complications of heart transplant
Contact: Jordan Reese, 215-707-4983 Porter Novelli Temple University Temple University study reports the New England Journal of Medicine, Philadelphia, Pennsylvania (USA) Treatment with a new immunosuppressant drug everolimus is much more effective in reducing the severity and frequency of serious complications of cardiac transplantation that the current treatment, according to a study in August 28 in the New England Journal of Medicine. The study was designed to evaluate the impact of everolimus on some complications such as acute rejection of heart transplant vasculopathy (also known as chronic rejection), the wall thickening of the arteries of heart transplant target reduction of blood flow coronary and location, patients lives in danger.are serious after a year of
cardiac allograft after transplantation to long-term complications and death, says researcher Howard iron, MD, director of advanced heart failure, the center of Temple University Hospital and Medical School. It is the main reason why many transplant patients do not survive long term. The impressive ability of everolimus on the frequency and severity of heart transplant could offer acceptance improve transplant patients a powerful tool for long-term survival - a major challenge in transplantation medicine.In addition, everolimus reduced the rate of acute rejection, a major problem for these patients in the first year after transplantation.More than 600 heart transplant patients enrolled in 52 medical centers in the United States, Canada, Europe and South America, making it
one of the inscriptions more extensive study in this patient population. More than 2,000 heart transplants are performed in the United States each year, the United Network for Organ Sharing (UNOS). The researchers also reported that everolimus significantly reduced the incidence of cytomegalovirus (CMV), a severe infection after transplantation and an important risk factor for heart transplant development and other issues.Pages: [1] 2 3